[The clinical characteristics of primary biliary cirrhosis in China: a systematic review].
OBJECTIVE
To summarize the clinical features, diagnosis and treatment of patients with primary biliary cirrhosis (PBC) in China.


METHODS
Systematic analysis of clinical characteristics by searching the Chinese literatures.


RESULTS
From 1955 to 2007, 2740 PBC patients were reported in 103 papers (duplicated reports were deleted). The detailed information of 985 patients from 16 papers were collected. Female : male was 6.82:1. The age range was 42 to 56.2-year-old. The time from onset to diagnosis was 12 to 98.4 months. The most common symptoms were fatigue (72.40%), jaundice (67.41%), anorexia (68.58%) and pruritus (45.60%). 20% patients were asymptomatic at onset. The most frequent physical signs were splenomegaly (57.53%), hepatomegaly (43.56%) and ascites (18.45%). Serum alkaline phosphatase (ALP) and gamma glutamyl transpeptidase (GGT) levels were markedly elevated in most of these patients. The immunological marks of AMA and M2 were positive in 88.98% and 82.65% patients, respectively. The most common comorbidity were Sjögren syndrome (9.14%), rheumatoid arthritis (3.95%) and diabetes type II (2.54%). Of the 507 patients treated with ursodeoxycholic acid (UDCA), 345 patients got complete or partial clinical biochemical response. The common complications were gastrointestinal bleeding (41.67%) and liver failure (41.67%). Liver transplantation was the only effective way for the treatment of the end-stage liver disease.


CONCLUSIONS
The clinical feature of primary biliary cirrhosis in China was similar to the overseas literatures. Further research should focus on epidemic investigation, early diagnosis, long term follow up of asymptomatic patients, immunological mechanism and the efficacy of liver transplantation.
Gu
Er-li
EL
Shanghai Jinganqu Central Hospital, Shanghai 200040, China.
Yao
Guang-bi
GB
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001323:Autoantibodies / Q000032:analysis*; D015415:Biomarkers / Q000097:blood; D002681:China / Q000453:epidemiology; D005260:Female; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D008105:Liver Cirrhosis, Biliary / Q000175:diagnosis* / Q000453:epidemiology* / Q000276:immunology / Q000628:therapy; D008111:Liver Function Tests; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D008930:Mitochondria, Liver / Q000276:immunology; D012189:Retrospective Studies; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use; D005723:gamma-Glutamyltransferase / Q000097:blood
D001323:Autoantibodies; D015415:Biomarkers; D007075:Immunoglobulin M; D014580:Ursodeoxycholic Acid; D005723:gamma-Glutamyltransferase; D000410:Alanine Transaminase